Jump to main content

Topic: Specialty Drugs

Part B Payment for Medicare Drugs
Overspending Driven by Oversized Single Dose Vials of Cancer Drugs
Pricing in the Market for Anticancer Drugs
Do High Drug Prices Drive Innovation, Or Hurt It?
The Just Price of Cancer Drugs
Reforming the Payment System for Medical Oncology
Cost Consequences of the 340B Drug Discount Program
In Cancer Care, Cost Matters
Limits on Medicare’s Ability to Control Rising Spending on Cancer Drugs
Targeted Drugs for Metastatic Renal Cell Carcinoma

Prev Next